Setup

FitLife Brands (FTLF) is a $0.1B nutritional supplement holding company. The Q1 2026 10-Q (filed May 14) resolved the binary covenant question and showed Irwin Naturals — acquired out of 363 bankruptcy in August 2025 — running materially ahead of prior estimates on Amazon.

What the Filing Says

Covenant compliance, explicit. Note 6: "The Company was in compliance with all covenants as of March 31, 2026 and December 31, 2025." Credit agreement: Senior Funded Debt / EBITDA ≤ 2.75x through Q2 2026, then tightens to 2.50x starting Q3 2026; Fixed Charge Coverage ≥ 1.25x. Total debt $41.8M, down $2.8M sequentially. No waiver, no amendment, no going concern. SOX 302/906 certifications signed. Item 3: zero defaults.

Irwin Amazon ramp. Online revenue: $311K (Q3 2025) → $1,428K (Q4 2025) → $2,554K (Q1 2026) — second consecutive +79% sequential print. MD&A: "annual run rate of approximately $9.5 million by the end of the first quarter of 2026." Irwin clean Q1 gross margin 34.0%, up from 28.0% in Q4 when the $1.045M inventory fair-value step-up was depressing the result. Step-up fully absorbed.

Legacy FitLife declining. Q1 2026 Legacy revenue $12.5M, -22% YoY (online -18%, wholesale -28%). Legacy gross margin stable at 41.2%. Consolidated revenue $25.3M (+59% YoY), gross margin 37.6%, EPS $0.17 vs $0.20 prior year — the interest expense delta ($735K vs $218K) is the drag, not operating performance.

What the Market Thinks

Trading at 5.77x forward P/E with no options available. Single-analyst coverage, ≈33% public float (CEO Dayton Judd owns 58.7% via Sudbury Holdings). Post-filing volume 0.7x average — no institutional accumulation yet despite a 10%+ price reaction in the week following the filing.

Factor regression over post-Irwin window (n=194 days, 8 models): 93-98% idiosyncratic variance across every specification. R² capped at 0.07. β to SPY essentially zero. Supplement peers (USNA, HLF) correlate 0.13-0.14. This is among the cleanest idio profiles in our book — not a sector trade.

Why the Gap Exists

Three specific reasons:

1. Thin coverage. Single sell-side analyst, micro-cap, ≈33% public float. The $9.5M run rate is buried in MD&A prose; the 34% clean Irwin margin requires reading the inventory step-up footnote. Sell-side hasn't synthesized.

2. Cross-ticker mechanism not connected. The Legacy decline mechanism is Amazon algorithm shift + Subscribe & Save unwind, NOT GLP-1 or category death. Public supplement peers (USNA, HLF, NUS, NATR) are MLM/DTC — zero GLP-1 mentions in their Q1 2026 10-Qs, premium supplement category bifurcated and growing (Thorne $229M → $650M; HLF organic +7.5% Q1 2026; VMS market +11% to 2027 per AlixPartners). FTLF's Amazon-exclusive Dr. Tobias takes the algorithm hit; Irwin's wholesale-anchored brand recognition gets the lift. Mechanism is mechanical and recoverable, not secular.

3. Doorway state just collapsed. Pre-filing, the covenant binary was unresolved; post-filing, it's clean both quarters.

Risks (Ranked by Impact)

1. Q3 2026 covenant step-down to 2.50x. Math: needs TTM EBITDA ≥$14.4M at ≈$36M projected debt. Q1 annualized EBITDA $13.2M is below; TTM at Q3 picks up four full Irwin quarters which plausibly bridges to $15-17M. Not free.
2. Legacy continues bleeding. -22% YoY is persistent. Bull requires deceleration to -10-15%; bear is -30%+.
3. Liquidity. Cash $1.2M is thin (working capital positive at $10.8M).
4. Founder concentration. Judd 58.7% — single point of failure, though aligned via $5-6M MTM existing options.
5. Tariff pass-through. China ingredient exposure unquantified. Industry-wide silence (USNA, HLF equally vague) — not FTLF-specific, but cost-side risk if pass-through fails.

Catalysts

What Would Change Our Mind

• Q2 Irwin online <$2.5M (sequential decline) → Driver 1 invalidated, exit
• Pre-Q2 covenant amendment 8-K → bear pillar reinstated
• 3+ director cluster insider selling → confidence break
• Q3 Legacy decline accelerates to -30%+ → mechanism not healing
• Q3 covenant amendment vs clean 2.50x → survival gate failed

Forward EV

Probability-weighted price targets:

EV(12mo) $12.30 (+17%, Sharpe 0.34). EV(18mo) $14.70 (+40%, Sharpe 0.53). Thesis needs 18 months to compound. DEMAND-type factor with a 365d+ half-life — patience premium is real, entry urgency is low.

Evidence